$-0.43 EPS Expected for aTyr Pharma, Inc. (LIFE)

February 15, 2018 - By Hazel Jackson

 $ 0.43 EPS Expected for aTyr Pharma, Inc. (LIFE)

Analysts expect aTyr Pharma, Inc. (NASDAQ:LIFE) to report $-0.43 EPS on March, 15.They anticipate $0.10 EPS change or 18.87 % from last quarter’s $-0.53 EPS. After having $-0.43 EPS previously, aTyr Pharma, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 3.08% or $0.1 during the last trading session, reaching $3.15. About 125,276 shares traded or 211.73% up from the average. aTyr Pharma, Inc. (NASDAQ:LIFE) has risen 12.96% since February 15, 2017 and is uptrending. It has underperformed by 3.74% the S&P500.

aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings Coverage

Among 7 analysts covering Life Technologies Corp (NASDAQ:LIFE), 1 have Buy rating, 3 Sell and 3 Hold. Therefore 14% are positive. Life Technologies Corp had 13 analyst reports since August 25, 2015 according to SRatingsIntel. Zacks downgraded aTyr Pharma, Inc. (NASDAQ:LIFE) on Tuesday, August 25 to “Hold” rating. The company was downgraded on Wednesday, December 14 by JP Morgan. The firm earned “Hold” rating on Wednesday, November 1 by BMO Capital Markets. The rating was maintained by BMO Capital Markets on Monday, August 14 with “Hold”. The stock of aTyr Pharma, Inc. (NASDAQ:LIFE) earned “Sell” rating by J.P. Morgan on Wednesday, February 14. The rating was maintained by JP Morgan with “Overweight” on Thursday, August 11. The firm earned “Underweight” rating on Wednesday, February 14 by JP Morgan. The stock of aTyr Pharma, Inc. (NASDAQ:LIFE) has “Buy” rating given on Thursday, September 7 by Piper Jaffray. Citigroup maintained aTyr Pharma, Inc. (NASDAQ:LIFE) on Tuesday, August 16 with “Neutral” rating. The firm earned “Market Perform” rating on Thursday, March 31 by William Blair.

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine therapeutics for patients suffering from severe and rare diseases. The company has market cap of $93.74 million. The firm develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy , early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy. It currently has negative earnings. The Company’s discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines.

More notable recent aTyr Pharma, Inc. (NASDAQ:LIFE) news were published by: Globenewswire.com which released: “aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923)” on November 27, 2017, also Globenewswire.com with their article: “aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides …” published on November 14, 2017, Globenewswire.com published: “aTyr Pharma to Participate at the BMO Prescriptions for Success Healthcare …” on November 21, 2017. More interesting news about aTyr Pharma, Inc. (NASDAQ:LIFE) were released by: Globenewswire.com and their article: “aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno …” published on December 21, 2017 as well as Globenewswire.com‘s news article titled: “aTyr Pharma to Participate at the Piper Jaffray 29th Annual Healthcare Conference” with publication date: November 21, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.